KV.A - Sector: Healthcare---Industry: Drug Delivery

[setravis]

Profile:  

KV Pharmaceutical Co.
One Corporate Woods Drive
Bridgeton, MO 63044
United States - Map
Phone: 314-645-6600
Fax: 314-646-3751
Website: http://www.kvpharmaceutical.com

Details  
Index Membership: N/A
Sector: Healthcare
Industry: Drug Delivery
Full Time Employees: 390


Business Summary  
K-V Pharmaceutical Company, together with its subsidiaries, develops, manufactures, acquires, and markets branded and generic/non-branded prescription pharmaceutical products. The company offers a range of dosage form manufacturing capabilities, including tablets, capsules, creams, liquids, and ointments. It has developed and patented various drug delivery and formulation technologies that are primarily focused in four principal areas: SITE RELEASE; tastemasking; oral controlled release; and oral quick dissolving tablets. In addition, K-V Pharmaceutical Company develops and markets specialty value-added raw materials, including drugs, directly compressible and microencapsulated products, and other products used in the pharmaceutical, industry, and other markets. The company markets its products directly to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies, and government entities. K-V Pharmaceutical Company was founded in 1942 and is headquartered in Bridgeton, Missouri.

[setravis]

UPDATE 1-K-V Pharma says Hologic resubmits filing for Gestiva

Tue Jul 13, 2010 1:20pm EDT

* Drug to prevent preterm birth

* Shares rise 14 pct

July 13 (Reuters) - K-V Pharmaceuticals Inc (KVa.N) said Hologic Inc (HOLX.O) has resubmitted its filing for marketing approval for its drug to prevent preterm birth, sending K-V's shares up as much as 14 percent.

In January 2009, Hologic, which had agreed to give U.S. and global rights of its drug Gestiva to K-V, received a complete response action letter from the U.S. Food and Drug Administration seeking additional data on the drug.

Gestiva is aimed at the prevention of preterm birth, especially in expectant women with a history of preterm delivery, the company said.

Most pregnancies last about 40 weeks, and babies born earlier than 37 weeks are considered premature.

Shares of KV Pharmaceuticals were up 9 percent at 70 cents in afternoon trade on Nasdaq. They touched a high of 73 cents earlier in the session.

[setravis]

Ramping up today for a nice looking 64% gain 
on some nice looking volume as well.
Put it on you radar !

[setravis]

100% upside potential.......
This low price stock has had its share of problems,
but they are shaping up for improvement.
Technicals are turning up and it can double in a short period of time.

Bull Flag.......

Technicals
Percentage Gainer

Last Price Quote is:
19.17%above 13-day MA
31.53%above 50-day MA
RS Rating: 94 

[setravis]

KV.A rocking in the Pre-Market 

K-V Pharmaceutical Company Clas(NYSE: KV-A)
Pre-Market Real-Time: 2.35  0.66 (39.05%) 8:47AM EDT

[setravis]

K-V Pharmaceutical Company Announces Completion of U.S. Food and Drug Administration Inspection and Approval to Return its First Product to Market

Press Release Source: K-V Pharmaceutical Company On Friday September 10, 2010, 8:30 am
ST. LOUIS, Mo., Sept. 10 /PRNewswire-FirstCall/ -- K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today that it has received notice from the U.S. Food and Drug Administration ("FDA") of the successful completion of an inspection of the Company's facilities and approval to return its first product to market.  Under the Company's Consent Decree, successful FDA inspections of the Company's quality systems, processes and facilities are expected to be required before K-V is permitted to resume manufacturing and shipment of particular products.  During the week of August 16, 2010, the FDA undertook an inspection of the Company's quality systems, manufacturing processes and facilities focusing on the first product dosage form for reintroduction by the Company into the marketplace.  The inspection was successfully completed.

The Company received notification from the FDA on September 8, 2010 of approval to ship into the marketplace the first product approved under the consent decree, i.e. Potassium Chloride.   The Company expects that initial shipments of its Micro-K®10mEq and Micro-K® 8mEq will begin the week of September 13, 2010.   The FDA is expected to conduct additional inspections with respect to other Company products before deciding whether other products may be manufactured and marketed.

Greg Divis, President of Ther-Rx Corporation and Interim President and Chief Executive Officer of K-V Pharmaceutical Company, stated, "Today marks a significant milestone in our efforts to restore business operations at K-V.  The successful FDA inspection of our facilities and approval of our return to market demonstrates our hard work and commitment to meeting and sustaining current Good Manufacturing Practices ("cGMP") requirements.  We are committed to continuing to move K-V through further successful inspections and to obtain additional product approvals from the FDA."

About K-V Pharmaceutical Company

K-V Pharmaceutical Company is a fully-integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded prescription products.  The Company markets its technology-distinguished products through Ther-Rx Corporation, its branded drug subsidiary.

For further information about K-V Pharmaceutical Company, please visit the Company's website at www.kvpharmaceutical.com.

Safe Harbor Statement

The information in this release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning the Company's operations, future results and prospects.  Such statements may be identified by the use of words like "plans," "expects," "aim," "believe," "projects," "anticipates," "commit," "intend," "estimate," "will," "should," "could," and other expressions that indicate future events and trends.

All statements that address expectations or projections about the future, and the Company's strategy for growth, product development, product launches, regulatory approvals, market position, acquisitions, revenues, expenditures and other financial results, are forward-looking statements.  All forward-looking statements are based on current expectations and are subject to risk and uncertainties.  In connection with the "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.   Such factors include (but are not limited to) the following:


1. the ability to continue as a going concern;

2.difficulties and uncertainties with respect to obtaining additional capital, as more fully described in Part I, Item 2 – "Management's Discussion and Analysis of Financial Condition and Results of Operations – Liquidity and Capital Resources" in the Quarterly Report on Form 10-Q for the quarter ended December 31, 2009 (the third quarter of the Company's fiscal year ended March 31, 2010 (the "Form 10-Q"));

3. the decisions the Company makes in order to maintain and increase our limited cash and financial resources may result in significant charges for impairment of inventory, property and equipment and intangible and other long-lived assets;

4. based on our cash balance and estimates of our operating expenditures, our existing cash and financial resources will not be sufficient to fund our operations beyond the quarter ending September 30, 2010, unless we are able to raise additional capital by selling assets or through external financing;

5. the consent decree between the Company and the FDA and the Company's suspension of the production and shipment of all of the products that it manufactures (other than the Potassium Chloride Micro-K® 10mEq and Micro-K® 8mEq products that are the subject of the just-received FDA letter) and the related nationwide recall affecting all of the other products that it manufactures, as well as the related material adverse effect on its revenue, assets and liquidity and capital resources, as more fully described in Part I, Item 2 – "Management's Discussion and Analysis of Financial Condition and Results of Operations – Background – Discontinuation of Manufacturing and Distribution; Product Recalls; and the FDA Consent Decree" in the Form 10-Q;

6. the possibility of further reducing the Company's operations, including further reductions of its employee base and significantly curtailing some or all of its efforts to meet the consent decree's requirements and return its approved products to market in order to maintain and attempt to increase its limited cash and financial resources, and related costs and accounting charges from taking such actions;

7. the plea agreement between the Company and the U.S. Department of Justice and the Company's obligations therewith, as well as the related material adverse effect, if any, on its revenue, assets and liquidity and capital resources, as more fully described in Note 20 – "Subsequent Events" of the Notes to the Consolidated Financial Statements in the Form 10-Q;
changes in the current and future business environment, including interest rates and capital and consumer spending;

8. the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized;

9. the possibility of not obtaining FDA approvals or delay in obtaining FDA approvals, including with respect to Gestiva™, as well as the number of preterm births for which Gestiva™ may be prescribed, its safety profile and side effects profile;

10. acceptance of and demand for the Company's new pharmaceutical products or current products upon their return to the marketplace;

11. the introduction and impact of competitive products and pricing, including as a result of so-called authorized generic drugs;

12. new product development and launch, including the possibility that any product launch may be delayed;

13. reliance on key strategic acquisitions;

14. the availability of raw materials and/or products manufactured for the Company under contract manufacturing agreements with third parties;

15. the regulatory environment, including regulatory agency and judicial actions and changes in applicable laws or regulations;

16. fluctuations in revenues;

17. the difficulty of predicting international regulatory approvals, including timing;

18. the difficulty of predicting the pattern of inventory movements by the Company's customers;

19.the impact of competitive response to the Company's sales, marketing and strategic efforts, including introduction or potential introduction of generic or competing products against products sold by the Company and its subsidiaries;

20. risks that the Company may not ultimately prevail in litigation, including product liability lawsuits and challenges to its intellectual property rights by actual or potential competitors or to its ability to market generic products due to brand company patents and challenges to other companies' introduction or potential introduction of generic or competing products by third parties against products sold by the Company or its subsidiaries including without limitation the litigation and claims referred to in Note 18 – "Commitments and Contingencies" of the Notes to the Consolidated Financial Statements in the Form 10-Q, and that any adverse judgments or settlements of such litigation, including product liability lawsuits, may be material to the Company;

21. the possibility that our current estimates of the financial effect of certain announced product recalls could prove to be incorrect;

22. whether any product recalls or product introductions result in litigation, agency action or material damages;

23. failure to supply claims by certain of the Company's customers, including CVS Pharmacy, Inc., that, despite the formal discontinuation action by the Company of its products, the Company should compensate such customers for any additional costs they allegedly incurred for procuring products the Company did not supply;

24. the satisfaction or waiver of the terms and conditions for the acquisition of the full U.S. and worldwide rights to Gestiva™ set forth in the previously disclosed Gestiva™ acquisition agreement, as amended;

25. the series of putative class action lawsuits alleging violations of the federal securities laws by the Company and certain individuals, as more fully described in Note 18 – "Commitments and Contingencies – Litigation and Governmental Inquiries" of the Notes to the Consolidated Financial Statements in the Form 10-Q;

26. the possibility that insurance proceeds are insufficient to cover potential losses that may arise from litigation, including with respect to product liability, failure to supply or securities litigation;

27. the informal inquiry initiated by the SEC and any related or additional government investigation or enforcement proceedings as more fully described in Note 18 – "Commitments and Contingencies – Litigation and Government Inquiries, of the Notes to the Consolidated Financial Statements" in the Form 10-Q;

28. the possibility that the pending investigation by the Office of Inspector General of the Department of Health and Human Services into potential false claims under the Title 42 of the U.S. Code as more fully described in Note 18 – "Commitments and Contingencies – Litigation and Government Inquiries" of the Notes to the Consolidated Financial Statements in the Form 10-Q could result in significant civil fines or penalties, including exclusion from participation in federal healthcare programs such as Medicare and Medicaid;

29. delays in returning, or failure to return, certain or many of the Company's approved products to the market, including loss of market share as a result of the suspension of shipments, and related costs;

30. the ability to sell or license certain assets, and the terms of such transactions;
the possibility that default on one type or class of the Company's indebtedness could result in cross default under, and the acceleration of, its other indebtedness;

31. the risks that present or future changes in the Board of Directors or management may lead to an acceleration of the Company's bonds or to adverse actions by government agencies or our auditors;

32. if a director of our company, or a shareholder with an ownership interest in our company of 5% or more, is excluded from participating in federal or state health care programs, then HHS may use its discretionary authority to also exclude our company from participation in federal healthcare programs;

33. the risk that even though the price and 30-day average price of the Company's Class A common stock and Class B common stock have recently again begun satisfying the quantitative listing standards of the New York Stock Exchange, including with respect to minimum share price and public float, the Company can provide no assurance that they will remain at such levels thereafter;

34. the risk that BDO will be unable to complete the audit of the Company's financial statements to be included in its annual report for its fiscal year ended March 31, 2010 on a timely basis which would impact the Company's compliance with New York Stock Exchange listing standards, and the Securities Exchange Act of 1934, as amended;

35. the risk that BDO will be unable to complete on a timely basis the review of the Company's financial statements to be included in its fiscal 2011 Form 10-Q's; and
the risks detailed from time-to-time in the Company's filings with the SEC.




This discussion is not exhaustive, but is designed to highlight important factors that may impact the Company's forward-looking statements.

Because the factors referred to above, as well as the statements included elsewhere in this press release, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by the company or on the Company's behalf, you should not place undue reliance on any forward-looking statements.  All forward-looking statements attributable to the Company are expressly qualified in their entirety by the cautionary statements in this "Cautionary Note Regarding Forward-Looking Statements" and the risk factors that are included under Part I, Item 1A – "Risks Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and referred to in Part II, Item 1A – "Risk Factors" in the Form 10-Q, as supplemented by the Company's subsequent SEC filings.   

Further, any forward-looking statement speaks only as of the date on which it is made and the Company is under no obligation to update any of the forward-looking statements after the date of this press release.  New factors emerge from time-to-time, and it is not possible for the Company to predict which factors will arise, when they will arise and/or their effects.  In addition, the Company cannot assess the impact of each factor on its future business or financial condition or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

[setravis]

100% upside potential.......
This low price stock has had its share of problems,
but they are shaping up for improvement.
Technicals are turning up and it can double in a short period of time.

Bull Flag.......

[setravis]

Makena Approval Jump-Starts KV Pharmaceutical
Speculation on successful turnaround (Long Recommendation)
There is a lot of smart money on this.

Day's Range: 2.60 - 4.23
52wk Range: 0.61 - 4.23
Volume: 15,601,229
Avg Vol (3m): 633,270

Technicals
Record Volume
Record Price High
Most Actives
Record Price Break Out
Gap Up
Percentage Gainer
RS Rating: 95 

[setravis]

Makena Approval Jump-Starts KV Pharmaceutical

A curious FDA approval sent a small pharmaceutical stock up 131% Friday. The company, KV Pharmaceutical, received approval for a drug that reduces the risk of premature birth in pregnant women, as Forbes reporter Matthew Herper noticed today.

KV Pharmaceutical is based in Bridgeton, Missouri, and has more debt than cash on its balance sheet. Shares were trading at $3.64 after the close Friday. The drug, called Makena, was approved ahead of an international trial that will be used to study whether the drug has a "clinical  benefit" in patients, the urgency being attributed to the need for a reduction in premature deliveries.

An FDA spokesperson said in a statement that, "Preterm birth is a significant public health issue in the United States. This is the first drug approved by the FDA that is indicated to specifically reduce this risk."

[setravis]

Today's closing chart...
Another move north!

[setravis]

K-V Pharma expects to raise $32M from stock sale
K-V Pharma says it will sell $32M in Class A stock and set up $130M financing facility

On Monday February 14, 2011, 1:01 pm EST
ST. LOUIS (AP) -- K-V Pharmaceutical Co. said Monday it expects to raise $32 million through a private placement of Class A stock, and is preparing to establish a financing facility worth $130 million.

The company said a group of institutional investors will buy 10 million shares for $3.25 per share. K-V will use $20 million to repay obligations under its credit agreement with U.S. Healthcare. The rest will be used for other corporate purposes, including the launch of its preventative pre-term birth treatment Makena. K-V expects the stock sale to close Thursday.

Makena is designed to reduce the risk of premature birth in women who have a history of preterm birth. The Food and Drug Administration approved the drug earlier this month.

K-V also said it expects to complete agreements on a $130 million financing facility Friday. It is setting up the facility through agreements with affiliates of Centerbridge Partners LP. The company secured a $60 million bridge loan from Centerbridge affiliates in November.

K-V said it will issue warrants to buy an additional 7.5 million Class A shares at $1.62 per share.

In afternoon trading, K-V's Class A shares rose 16 cents, or 3.7 percent, to $4.54.

[setravis]

Look at it this way...they get $32.5 million in cash instantly from an investor whose best interest is to hold onto the stock long term and sell off shares at a later date...after KV stabilizes.
Considering the price was $1.33 per share a week ago,
this is a vote of confidence from institutions that things are looking up.

Day's Range: 3.85 - 6.53
52wk Range: 0.61 - 6.53
Volume: 7,776,931
Avg Vol (3m): 885,794
Market Cap: 325.58M

Technicals
Record Price High
Percentage Gainer

100% upside potential.......
This low price stock has had its share of problems,
but they are shaping up for improvement.
Technicals are turning up and it can double in a short period of time.

Bull Flag.......

[setravis]

Expect the coming shakeout...Hold your shares...
There is a bright Future in KV.A and technically speaking is looking like a Champ!
Also check this out...
http://holeinonestocks.net/v7/index.php?code=KV-A

Day's Range: 7.68 - 8.73
52wk Range: 0.61 - 8.73
Volume: 4,535,952
Avg Vol (3m): 1,217,370

Technicals
Record Price High
Percentage Gainer

Last Price Quote is:
83.72%above 13-day EMA
185.64%above 50-day EMA
RS Rating: 98 

[setravis]

New frontiers in investing
With its stock soaring after FDA approval for its drug designed to reduce the risk of preterm birth, KV Pharmaceuticals figures it's a good time to raise some cash. The biotech will be raising $32 million in a private placement and will be setting up a $130 million financing facility, too. The funds it receives from the stock sale will be used in part to launch the drug Makena.

Finished strong...I'm impressed
Past Week's Change
108.76%


Day's Range: 8.25 - 10.13
52wk Range: 0.61 - 10.13
Volume: 9,123,105
Avg Vol (3m): 1,394,160

[setravis]

Stock offerring after FDA approval...
Retest the moving averages with dilution, then consolidate uptrend!

KV Pharmaceutical was the market's biggest winner, more than doubling during the trading week of 14 Thur 18 Feb. It's been a huge month for the biotech, which began February neglected by Mr. Market at $1.61. It's been a six-bagger in February alone! KV Pharmaceutical has been on a tear since the FDA approved Makena, the only treatment on the market to reduce the risk of preterm birth in women with a history of singleton spontaneous preterm birth.

Geeknet could have screened Revenge of the Nerds after a blowout quarter. The company that attracts almost 55 million unique monthly visitors to its portfolio of tech-heavy websites, including SourceForge, Slashdot, and ThinkGeek, saw quarterly revenue spike 53% to $50 million. Net income from continuing operations more than tripled to $0.77 a share.

Company                                          2/18/11      Weekly Gain
KV Pharmaceutical (NYSE: KV-A         $9.86             125%


Day's Range: 7.50 - 8.80
52wk Range: 0.61 - 10.13
Volume: 3,457,769
Avg Vol (3m): 1,566,630
Market Cap: N/A
P/E (ttm): N/A
EPS (ttm): -5.69
Div & Yield: N/A (N/A)

Technicals
Percentage Gainer

Last Price Quote is:
24.80%above 13-day EMA
109.61%above 50-day EMA
RS Rating: 98